In the preceding three months, 7 analysts have released ratings for Fulcrum Therapeutics (NASDAQ:FULC), presenting a wide array of perspectives from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $9.0, a high estimate of $23.00, and a low estimate of $2.00. A 42.57% drop is evident in the current average compared to the previous average price target of $15.67.

Decoding Analyst Ratings: A Detailed Look

A comprehensive examination of...